Zostavax

Persistence of Protection by Shingrix

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

VZV Vaccine for Hematopoietic Stem Cell Transplantation

Safety and Immunogenicity of a Zoster Vaccine in SLE

Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Zoster Vaccine Response in the Frail Elderly

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

Herpes Zoster Vaccine for Bone Marrow Transplant Donors

ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors

Optimal Timing of Zoster Vaccine After Zoster Illness

Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™

Safety Study of NBP608 in Healthy Adult Volunteers

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over